Triple Negative Breast Cancer Metastatic clinical trials

Explore recruiting triple negative breast cancer metastatic clinical trials.

Recruiting triple negative breast cancer metastatic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Triple Negative Breast Cancer Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

"TOPOLOGY" : A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis.

France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer

France, Sweden, Poland, Spain, Finland, Portugal +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Triple Negative Breast Cancer Metastatic trials by city

Triple Negative Breast Cancer Metastatic in Toronto Triple Negative Breast Cancer Metastatic in Vancouver Triple Negative Breast Cancer Metastatic in Montreal Triple Negative Breast Cancer Metastatic in Calgary Triple Negative Breast Cancer Metastatic in Edmonton Triple Negative Breast Cancer Metastatic in Ottawa Triple Negative Breast Cancer Metastatic in Winnipeg Triple Negative Breast Cancer Metastatic in Quebec City Triple Negative Breast Cancer Metastatic in Hamilton Triple Negative Breast Cancer Metastatic in Kitchener Triple Negative Breast Cancer Metastatic in London Triple Negative Breast Cancer Metastatic in Halifax Triple Negative Breast Cancer Metastatic in New York Triple Negative Breast Cancer Metastatic in Los Angeles Triple Negative Breast Cancer Metastatic in Chicago Triple Negative Breast Cancer Metastatic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease